Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (SIGY) is a development-stage medical technology company whose news flow centers on its dialysis-like blood purification therapies and related corporate developments. Company announcements highlight progress on Sigyn Therapy, a novel blood purification technology aimed at pathogen-associated inflammatory disorders, as well as its oncology-focused platforms ImmunePrep, ChemoPrep, and ChemoPure.
News releases frequently cover clinical and regulatory milestones, such as plans for first-in-human feasibility studies of Sigyn Therapy in end-stage renal disease patients with endotoxemia and concurrent inflammation, drafting of an Investigational Device Exemption for submission to the U.S. Food and Drug Administration, and discussions of potential Breakthrough Device submissions. Investors can also find updates on annual and quarterly financial results, including the filing of Form 10-K and other SEC reports referenced in company communications.
Sigyn Therapeutics also issues news about capital markets and corporate actions, including its 1-for-40 reverse stock split and efforts to meet listing requirements for The Nasdaq Capital Market. Coverage includes participation in emerging growth and small-cap conferences, such as the Emerging Growth Conference and LD Micro Main Event, where management presents updates on the companys therapeutic pipeline and development plans.
In addition, third-party research coverage, such as reports from Goldman Small Cap Research, is sometimes summarized in press releases that describe Sigyn Therapeutics as a developer of next-generation blood purification therapies for life-threatening conditions without FDA-approved treatments. For investors and observers, the SIGY news feed offers a consolidated view of clinical planning, technology development, financing steps, and investor outreach activities related to the companys blood purification and oncology-support platforms.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) announced that its Chairman and CEO, Jim Joyce, will present a live webinar on February 16, 2021, at 12:00 pm ET. The company focuses on treating life-threatening inflammatory conditions caused by Cytokine Storm Syndrome, aiming to address a significant unmet need in global health. Sigyn Therapy is designed to mitigate this syndrome, which is linked to high mortality rates, especially during COVID-19. This press release includes forward-looking statements about potential risks and uncertainties affecting the company's performance.